AU2021100530A4 - Mongolian medicine composition for treating diabetes, hyperlipidaemia and primary hyperviscosity - Google Patents

Abstract

Austracy The present invention discloses a Mongolian medicine composition for treating diabetes, hyperlipidaemia and primary hyperviscosity with excellent curative effects. The Mongolian medicine composition is prepared from elecampane inula root, Fructus gardeniae, platycodon grandiflorus, coptis chinensis and sappanwood. The Mongolian medicine composition has the advantages of significant curative effects on corresponding symptoms, fast efficacy and no toxic or side effect. 1

Description

Austracy

The present invention discloses a Mongolian medicine composition for treating diabetes, hyperlipidaemia and primary hyperviscosity with excellent curative effects. The Mongolian medicine composition is prepared from elecampane inula root, Fructus gardeniae,platycodon grandiflorus, coptis chinensis and sappanwood. The Mongolian medicine composition has the advantages of significant curative effects on corresponding symptoms, fast efficacy and no toxic or side effect.

Description

MONGOLIAN MEDICINE COMPOSITION FOR TREATING DIABETES, HYPERLIPIDAEMIA AND PRIMARY HYPERVISCOSITY

Technical Field

The present invention relates to the field of preparation of Mongolian medicines, and particularly relates to a Mongolian medicine composition for treating diabetes, hyperlipidaemia and primary hyperviscosity.

Background

For awareness of diabetes, symptoms such as thirst and diuresis were first recorded in The Yellow Emperor's Canon of Internal Medicine. Three-high symptoms have been completely recorded in Chapter consumptive thirst of Golden Chamber Synopsis written by Zhongjing Zhang of Han Dynasty <the 2nd century AD>. The history of diabetes in western countries is: Aulus Cornelius from 20 BC to 56 AD became the first person to describe the symptoms of diabetes in Europe. Cowley described pancreatic diseases of diabetic patients and morphological characteristics of pancreas islet in 1788. VonMerring and Minkowski observed in 1889that a dog suffered from diabetes after its pancreas was removed. Animal proinsulin was discovered in 1921. In memory of the inventor of insulin, the birthday of Banting, a Nobel Prize winner, i.e., November 14 was established as 'World Diabetes Day' by World Health Organization and International Diabetes Federation every year. At present, transplanted pancreases and artificial pancreas islets are researched for treating the diabetes around the world. Diabetic symptoms are recorded in Mongolian medicine as follows: diabetes was mentioned in the four tantras of nectar in Mongolian Medical Classics; Xiaoshou Badagan was mentioned in Lantabu (Mongolian); and diabetes and other diseases were mentioned in the four medical tantras. The Encyclopedia of Chinese Medicine (Mongolian Medicine) with the first record of Type 2 Diabetes was published in

Description

1987. The Type 1 Diabetes was recorded in Mongolian InternalMedicine Textbook published in 1987. The Type 2 Diabetes was recorded in Mongolian Internal Medicine Textbook published in 2011. The diabetes is a frequently-occurring disease and a common disease, as well as a worldwide public health problem that severely threatens human health. An incidence rate of the diabetes is sharply increased. The prevalence rate is also rapidly increased in China; an incidence rate of adults is up to 9.7%; a ratio of early diabetes is up to 15.5%; and more seriously, 60% of the diabetic patients have not been diagnosed. Partial patients diagnosed with diabetes are not treated, while blood glucose control of one half of the patients is unsatisfactory during medical treatment. The diabetes shows a significant younger trend. 'Career-oriented' people at an age of 40-50 have the highest incidence rate of diabetes. China has 92.4 million diabetic patients, and becomes the first big country with diabetes. However, there is not enough awareness for diabetes; and since people do not pay enough attention to the diabetes at an earlier stage, the disease is aggravated, and multiple complications are combined, thereby finally causing physical disabilities. The diabetes means a series of metabolic disorder syndromes of sugar, protein, fat, water and electrolyte initiated by pancreas islet function decrease and insulin resistance caused by various pathogenic factors such as genetic factor, immune dysfunction, microbial infection and toxins thereof, free radical toxins and mental factors that act on bodies. The diabetes is mainly characterized by high blood glucose clinically, and is called a 'silent killer' in foreign countries. According to the statistics, the number of the diabetic patients in China is up to 92.4 million now. In 2010, the prevalence rate of male adult diabetic patients was up to 12.1%, and the prevalence rate of female adult diabetic patients was up to 11%; and the prevalence rate of urban residents was up to 14.3%, and the prevalence rate of rural residents was up to 10.3%. According to previous estimation of International

Description

Diabetes Federation, there are more than 300 million diabetic patients worldwide. The newly released Chinese diabetes incidence data shows that, 1/3 of the global diabetic patients come from China. However, compared with the number in 2007, such a figure shows that 22 million diabetic patients have been increased in China in three years, which is almost equivalent to the total national population of Australia. Professor Guang Ning has said, China is one of the countries having the highest incidence rate of diabetes in Asia, and an absolute number of the incidence rate is the highest all over the world. A ratio of early diabetes is up to 15.5%, i.e., postprandial blood glucose is 7.8-11.1 (that is, impaired glucose tolerance), or fasting blood-glucose is 6.1-7.0 (that is, impaired fasting glucose). However, the blood glucose of about 2/3 of the diabetic patients in China is not adequately controlled. Thus, for many medical workers, to conquer diabetes as soon as possible is the trend of social responsibility. The diabetes was recorded in The Four Medical Tantras in Mongolian medicine; and systematic treatment descriptions are recorded in The Four Medical Tantras and have been verified in long-term clinical practice. In recent years, in combination with Mongolian medicine and Western medicine during clinical application, excellent curative effects on the diabetes are achieved. Therefore, in the present invention, it is very necessary to conduct systematic clinical observational study on the diabetes, make full use of advantages of the Mongolian medicine and develop an optimal prescription for treating the diabetes so as to increase an improvement rate and prevent and decrease the complications.

Summary

A purpose of the present invention is to provide a Mongolian medicine composition for treating diabetes, hyperlipidaemia and primary hyperviscosity with excellent curative effects.

Description

Particularly, the Mongolian medicine composition is prepared from the following raw materials in parts by weight: 1-2 parts of elecampane inula root, 3-6 parts of Fructus gardeniae, 10-15 parts of platycodon grandiflorus, 5-10 parts of coptis chinensis and 5-8 parts of sappanwood. Preferably, the Mongolian medicine composition includes the following raw materials in parts: 1.5 parts of elecampane inula root, 4.5 parts of Fructus gardeniae, 12 parts of platycodon grandiflorus, 8 parts of coptis chinensis and 6 parts of sappanwood. The Mongolian medicine composition in the present invention can be prepared into any dosage forms suitable to be taken by patients by a well-known method in the art, such as powder, tablets and capsules. Particularly, considering convenience in preparation and administration, the Mongolian medicine composition can be prepared into powder. A use method is as follows: the medicine is taken once by 2.5-3 g with warm boiled water for 3-4 times every day. A course of treatment lasts 1-3 months. Selection basis 1, Semi-hotness and oiliness of a guiding drug Xila with major bitter taste; 2, Sharpness of the guiding drug Xila with major shielding property; 3, Oiliness of a guiding drug Badagan with an oil-free effect; 4, Retrogradation of the guiding drug Badagan with major slight efficacy; and 5, Effects of clearing blood heat, removing turbid blood and nourishing hemochrome. In the present invention, during design of technical solutions, synergistic effects among the various ingredients are fully considered, and the ingredients and proportions are optimized at three different stages. Meanwhile, the present invention also considers that some ingredients may have toxic and side effects, such as side effects of the Fructusgardeniae.

A

Description

In Pharmacology of Mongolian Medicine, when alcohol extract extracted from the Fructus gardeniae is injected into stomachs of mice at a large dose (107.48g/kg), temporary damage of liver function may be caused; however, the amount of the Fructus gardeniae contained in the Mongolian medicine composition in the present invention taken by 7.5-12 g per day is about 1/4280 of the above liver function damage, and thus the liver function is not damaged. Chinese Pharmacopoeia: toxic or side effects of the Fructus gardeniae are not specified. Great Dictionaryof Chinese Medicine (1984 version): the toxic or side effects are not given; and an oral administration amount is 10-20 g each time, which is far greater than the amount of the Fructus gardeniae contained in the Mongolian medicine composition in the present invention taken by 7.5-12 g per day.

Detailed Description

Embodiment 1 1 part of elecampane inula root, 3 parts of Fructus gardeniae, 10 parts of platycodon grandiflorus, 5 parts of coptis chinensis and 5 parts of sappanwood were selected and uniformly mixed; the mixture was ground into fine powder; and the prepared powder was packed at a unit dose of 2.5 g. Embodiment 2 1.5 parts of elecampane inula root, 4.5 parts of Fructusgardeniae, 12 parts of platycodon grandiflorus, 8 parts of coptis chinensis and 6 parts of sappanwood were selected and uniformly mixed; the mixture was ground into fine powder; and the prepared powder was packed at a unit dose of 2.5 g. Embodiment 3 2 parts of elecampane inula root, 6 parts of Fructus gardeniae, 15 parts of platycodon grandiflorus, 10 parts of coptis chinensis and 8 parts of sappanwood

Description

were selected and uniformly mixed; the mixture was ground into fine powder; and the prepared powder was packed at a unit dose of 2.5 g. Embodiment 4 Pharmacological experiment data Clinical curative effects of diabetic patients in outpatient treatment were observed from September 2011 to September 2014. Diagnosis standard Mongolian medicine diagnosis standard The diagnosis standard of Ethnologic Medical Diagnosis and Treatment Scheme on Type 2 Diabetesfor 7 Nationalitiesand 41 Disease Entities Published by Department of Medical Administration of National Administration of TraditionalChinese Medicine is the basis. Primary symptoms: polydipsia, diuresis, polyphagia, emaciation and weakness. Secondary symptoms: thirst, sweet mouth, favor of cool, dizziness, lower limb weakness, palpitation, insomnia, skin itch, infection and blurred vision. Pulse condition: slow and fine. Urine: light yellow, turbid and uncertain amount Tongue: thicker tongue coat (yellow and white) Mongolian medicine syndrome diagnosis standard Badagan diabetes: obesity, preferred to Badagan constitution, tiredness, waist soreness, limb atony, weakness, indigestion, slow pulse, thick and white tongue coat, and much white urine. Heyixila diabetes: palpitation, insomnia, skin prick, thirsty polydipsia, poor sleep, rough skin, fine pulse, yellow tongue coat, and much yellow urine. Qisuxila diabetes: dizziness, hot eyes, thirst, overeating, emaciation, constipation, palpitation, bromidrosis, fine pulse, yellow and thick tongue coat and yellow and smelly urine.

Description

Western medicine diagnosis standard Early diabetes diagnosis standard Patients with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are totally called prediabetes patients. Impaired fasting glucose (IFG) diagnosis standard: Based on Version 7 of InternalMedicine: Fasting blood-glucose of 6.1-6.9 mmol/L Postprandial blood glucose less than 7.8 mmol/L Impaired glucose tolerance (IGT) diagnosis standard: Based on Version 7 of InternalMedicine: Fasting blood-glucose less than 7.0 mmol/L Postprandial blood glucose of 7.8-11.0 mmol/L Diabetes diagnosis standard: Referring to Guidelines for Diabetes Prevention and Treatment in China (2011) and based on Version 7 of InternalMedicine: Fasting blood-glucose more than or equal to 7.0 mmol/L or 2-hour post-meal blood glucose more than or equal to 11.1 mmol/L or diabetic symptoms + blood glucose at any time more than or equal to 11.1 mmol/L or glycosylated hemoglobin more than or equal to 6.5% Case selection standard Meeting type 2 diabetes diagnosis standard: Mild cases (blood glucose less than or equal to 10 mmol/L) Patients who can orally take Mongolian medicines Patients who can cooperate with the follow-up People with the consent of patients Case exclusion standard

Description

Severe cases, i.e., blood glucose more than or equal to 10 mmol/L, or combined with other severe complications in heart, brain and kidney. Type 1 diabetes and other types of diabetes were excluded. People with allergic constitution, that is, people who were allergic to medication People who did not cooperate with follow-up clinic Case sources Patients who saw the doctors at Outpatient and Inpatient Departments of Alxa League Mongolian Medicine Hospital from September 2011 to September 2014 and met diagnosis standards of type 2 diabetes General conditions of cases: 100 patients included 56 male patients and 44 female patients; the minimum age was 40, and the maximum age was 74; and the patients were randomly divided into two groups according to a treatment sequence: A treatment group: 50 patients, including 28 male patients and 22 female patients; the minimum age was 39, and the maximum age was 74; and an average age was 45.3+1.8; A control group: 50 patients, including 27 male patients and 23 female patients; the minimum age was 39, and the maximum age was 67; and an average age was 43.5+4.2. The patients in the two groups had no statistical significance of differences in aspects such as gender and age, and had comparability (P>0.05). Treatment group Principle of treatment Clearing Qisuxila heat, balancing three highs and performing symptomatic treatment according to the illness state Treatment method: The Mongolian medicine composition in the present invention was taken by 3 g each time with boiled water during breakfast, lunch and dinner three times a day.

Q

Description

Control group Principle of treatment Diet control and exercise therapy Treatment method: Strict diet control, exercise and weight loss Evaluation standard of curative effects Excellent: the fasting blood-glucose was significantly decreased, and symptoms disappeared. Effective: the symptoms were improved, and the fasting blood-glucose had no obvious change. Ineffective: the symptoms before and after treatment and the fasting blood-glucose had no obvious change. The total effective rate was equal to (excellent patients+ effective patients)/the total patients. Statistical treatment Data was subjected to statistical analysis by SPSS 13.0 software. All the measurement data were represented by mean standard deviation (x s); the groups were compared by t test and variance analysis; and P<0.05 meant that the difference had statistical significance. Results Through comparison of the curative effects in the two groups, the treatment group included 15 excellent patients, 30 effective patients and 5 ineffective patients; and the control group included 4 excellent patients, 27 effective patients and 19 ineffective patients. The total effective rate in the two groups was respectively 90.0% and 62.0%. The difference had statistical significance (P<0.05) See Table 1 Table 1 Comparison n of the curative effects in the two groups, n(%)

Description

Group Number of cases Excellent Effective Ineffective Total effective rate (%)

Treatment group 50 15 30 5 90

Control group 50 4 27 19 62

Through comparison of clinical symptoms, sign fading and blood glucose decrease time in the two groups, symptom fading time of the treatment group: polydipsia, overeating and diuresis within (5.60.70) d, and blood glucose decrease within (5.300.99) d; the symptom fading time of the control group: polydipsia, overeating and diuresis within (11.60.54) d, and blood glucose decrease within (10.220.81) d; cure time of the treatment group and the control group was respectively (30.02+0.99) d and (45.08+0.98) d; and through comparison of the two groups, the difference had statistical significance (P<0.05) See Table 2 Table 2 Comparison of symptoms and sign improvement time in two groups (x s, d)

Group n Symptom fading time Blood glucose decrease time Cure time (Hour)

Treatment group 50 5.60+0.70 5.30+0.99 4.02+0.99

Control group 50 11.6+0.54 10.22+0.81 5.08+0.98

P value P<0.05 P<0.05 P<0.05

Special cases Case 1 A patient XX Bai, male, 42, employee, first treated on February 10, 2014. The patient was obviously weak in recent two years, sweated more, urinated more sometimes, and had higher blood glucose for three years without treatment. Previous test results were as follows: On June 25, 2012, the fasting blood-glucose checked in the outpatient of the hospital was 9.8 mmol/L; On March 27, 2013, the fasting blood-glucose checked in Ningxia Corps Hospital was 8.69 mmol/L;

1iA

Description

On February 10, 2014 (the first treatment date of the department), the checked fasting blood-glucose was 9.9 mmol/L. Diagnosis: type 2 diabetes Treatment: the Mongolian medicine composition in the present invention was taken by 3 g each time for three times a day with warm boiled water during breakfast, lunch and dinner. The patient saw the doctor for the second time on May 26, 2014. Symptoms of the patient such as weakness and hyperhidrosis were improved; the checked fasting blood-glucose was 7.6 mmol/L; and the treatment was the same as above. The patient saw the doctor for the third time on July 25, 2014. The patient had no body discomfort; the checked fasting blood-glucose was 7.1 mmol/L; and the treatment was the same as above. Case 2 A patient XX Wang, female, 57, the Han nationality, resident The patient was first treated on April 18, 2014. The patient suffered from weakness and nausea, lost weight by about 3 Kg and urinated more in nearly 1 month. During treatment in Central Hospital on April 14, 2014, the fasting blood-glucose was 18.53 mmol/L; 2-hour post-meal blood glucose was 17.87 mmol/L; glycosylated hemoglobin content was 12.5%; checked insulin was 5.4 mmol/L; and C-peptide content was 1.26 ng/nL. The patient was treated at the outpatient department of the hospital for oral Mongolian medicine treatment in April 18, 2014. Notes: the diet of the patient was dominated by sweets. Diagnosis: type 2 diabetes Treatment: 1, regular diabetic diet 2, The Mongolian medicine composition in the present invention was taken by 3 g each time for four times a day with warm boiled water during breakfast,

Description

lunch and dinner; and the Mongolian medicine composition was taken with warm boiled water by 3 g before late sleep. The patient saw the doctor for the second time on June 10, 2014. The above symptoms of the patient disappeared; the checked fasting blood-glucose was 6.7 mmol/L; and the treatment was the same as above. On the World Diabetes Day of November 14, 2014, the checked fasting blood-glucose was 7.3 mmol/L. Then, the Mongolian medicine composition in the present invention was continuously taken by 3 g each time with the warm boiled water during breakfast, lunch and dinner. Case 3 A patient XX Wu, male, 58, employee in the hospital During physical examination for employees in the hospital in September 2014, it was discovered that, the patient had total cholesterol of 7.22 mmol/L, low density lipoprotein of 5.82 mmol/L, uric acid of 467 pmmol/L and glutamic-pyruvic transaminase of 97.8 p/L. The patient was hospitalized at Department of endocrinology of the hospital on October 11, 2014 due to hyperlipidaemia and liver function damage. Through hospital inspection, the patient had total cholesterol of 7.4 mmol/L, low density lipoprotein of 5.81 mmol/L, uric acid of 483 pmmol/L, glutamic-pyruvic transaminase of 169.6 p/L, glutamic oxalacetic transaminase of 63 p/L and transglutaminase of 233 p/L. Diagnosis: 1, hyperlipidaemia 2, Liver function damage Treatment: due to the liver function damage, stanin lipid-lowering medicines cannot be used. Therefore, the Mongolian medicine composition in the present invention was taken by 3 g each time with the warm boiled water during breakfast, lunch and dinner.

1*')

Description

On October 27, 2014, the test results included total cholesterol of 4.73 mmol/L, low density lipoprotein of 3.12 mmol/L, uric acid of 388 pmmol/L, glutamic-pyruvic transaminase of 80.1 p/L and transglutaminase of 117p/L. The hyperlipidaemia was cured and the patient was discharged from hospital. Case 4 A patient XX Han, male, 50, first treated on October 22, 2015. The patient lost weight by about 6 Kg and had symptoms such as thirst, polydipsia, diuresis and polyphagia nearly half a year. When treated in the central hospital, biochemical test results of the patient included the fasting blood-glucose of 11.27 mmol/L and low density lipoprotein of 4.36 mmol/L. The patient was treated at the outpatient department of the hospital for oral Mongolian medicine treatment. When checked in the hospital on October 22, 2015, the patient had the fasting blood-glucose of 10.5 mmol/L, postprandial blood glucose of 17.7 mmol/L and routine urine test result of glucose +2. Diagnosis: 1, type 2 diabetes 2, Hyperlipidaemia Treatment: the Mongolian medicine composition in the present invention was taken by 3 g each time for four times a day, taken with the warm boiled water during breakfast, lunch and dinner, and taken with the warm boiled water by 3 g before late sleep. The patient saw the doctor for the second time on November 10, 2015. The symptoms of the patient such as polydipsia, diuresis and polyphagia disappeared; the test results included the fasting blood-glucose of 9.4 mmol/L, the 2-hour post-meal blood glucose of 13.7 mmol/L and the low density lipoprotein of 2.96 mmol/L; and the treatment was the same as above.

Description

The patient saw the doctor for the third time on November 24, 2014. The test results included the fasting blood-glucose of 8.5 mmol/L and the 2-hour post-meal blood glucose of 12.2 mmol/L; and the treatment was the same as above. Case 5 A patient XX Li, female, 83, having a case number of 12558 The patient itched all over for more than 1 year. Itching was aggravated for a week, and the patient was hospitalized on January 06, 2016. After hospitalization, test results of the patient included glycosylated hemoglobin content of 6.7%, fasting blood-glucose of 7.3 mmol/L, total cholesterol content of 7.12 mmol/L, low density lipoprotein of 5.07 mmol/L and routine urine test result of glucose +3. Determination of hemorheology: Test value Reference value

Whole blood viscosity Low shear (mpa.s)/ 10 (1/s) 23.43 6.8-10.78

Medium shear (mpa.s)/ 60 (1/s) 9.35 4.5-6.59

High shear (mpa.s)/ 150 (1/s) 6.90 3.73-5.01

Whole blood reduced viscosity (low shear) 51.45 11.02-19.84

Whole blood reduced viscosity (medium shear) 18.55 6.25-10.51

Whole blood reduced viscosity (high shear) 12.84 4.63-8.26

Diagnosis: 1, Senile skin pruritus 2, Type 2 diabetes 3, Hyperlipidaemia 4, Blood hyperviscosity Treatment: for antianaphylactic treatment of Western medicine and treatment of hyperglycemia, hyperlipidaemia and blood hyperviscosity, the Mongolian medicine composition in the present invention was taken by 3 g each time, taken with the warm boiled water during breakfast, lunch and dinner, and taken with the warm boiled water by 3 g before late sleep.

1A

Description

On February 29, 2016, test results of the patient included fasting blood-glucose of 6.4 mmol/L, total cholesterol content of 5.82 mmol/L and low density lipoprotein of 3.67 mmol/L. Determination of hemorheology: Test value Reference value

Whole blood viscosity Low shear (mpa.s)/ 10 (1/s) 17.6 6.8-10.78

Medium shear (mpa.s)/ 60 (1/s) 5.98 4.5-6.59

High shear (mpa.s)/ 150 (1/s) 4.05 3.73-5.01

Whole blood reduced viscosity (low shear) 36.70 11.02-19.84

Whole blood reduced viscosity (medium shear) 14.50 6.25-10.51

Whole blood reduced viscosity (high shear) 8.96 4.63-8.26

The results showed that, after the Mongolian medicine composition in the present invention was orally taken for one and half months, the whole blood viscosity and the whole blood reduced viscosity were significantly decreased. Case 6 A patient XX Bai, male, 68, first treated on June 23, 2015. The patient frequently urinated more in nearly two months, suffered from thirst and weakness and lost weight by about 3 Kg. Thus, the patient was subjected to outpatient treatment in Endocrinology Department of the hospital. Through body examination, the patient had poor skin elasticity and no other positive signs; and both the liver function and renal function in test items were normal. Four blood lipid items: Test value Reference value

Total cholesterol 6.02 mmol/L 2.85-5.7 mmol/L

Triglyceride 3.41 mmol/L 0.45-1.7 mmol/L

High-density lipoprotein 1.28 mmol/L 0.78-2 mmol/L

Low-density lipoprotein 4.36 mmol/L 0-3.7 mmol/L

Description

Determination of hemorheology: Test value Reference value

Whole blood viscosity Low shear (mpa.s)/ 10 (1/s) 13.68 6.8-10.78

Medium shear (mpa.s)/ 60 (1/s) 8.97 4.5-6.59

High shear (mpa.s)/ 150 (1/s) 6.05 3.73-5.01

Whole blood reduced viscosity (low shear) 25.53 11.02-19.84

Whole blood reduced viscosity (medium shear) 13.26 6.25-10.51

Whole blood reduced viscosity (high shear) 9.38 4.63-8.26

Test values of blood glucose:

Test value Reference value

Fasting blood-glucose 13.6 mmol/L 3.1-6.19 mmol/L

Random blood glucose 18.2 mmol/L >11.1 mmol/L

Diagnosis: 1, Diabetes 2, Hyperlipidaemia 3, Blood hyperviscosity Treatment: the Mongolian medicine composition in the present invention was taken by 3.0 g each time for 4 times a day. Method: the Mongolian medicine composition was taken with the warm boiled water half an hour before breakfast, lunch and dinner and at 21:00 pm. The patient saw the doctor for the second time on September 03, 2015. The patient had inconspicuous thirst and no discomfort and urinated normally. Four blood lipid items: Test value Reference value

Total cholesterol 5.72 mmol/L 2.85-5.7 mmol/L

Triglyceride 1.85 mmol/L 0.45-1.7 mmol/L

High-density lipoprotein 1.29 mmol/L 0.78-2 mmol/L

Low-density lipoprotein 3.67 mmol/L 0-3.7 mmol/L

1A

Description

Test values of blood glucose:

Test value Reference value

Fasting blood-glucose 9.8 mmol/L 3.1-6.19 mmol/L

Random blood glucose 13.6 mmol/L >11.1 mmol/L

Determination of hemorheology: Test value Reference value

Whole blood Low shear (mpa.s)/ 10 (1/s) 9.8 6.8-10.78 viscosity Medium shear (mpa.s)/ 60 (1/s) 6.69 4.5-6.59

High shear (mpa.s)/ 150 (1/s) 4.78 3.73-5.01

Whole blood reduced viscosity (low shear) 20.8 11.02-19.84

Whole blood reduced viscosity (medium shear) 11.8 6.25-10.51

Whole blood reduced viscosity (high shear) 9.35 4.63-8.26

Conclusions: the above examples indicate that, the Mongolian medicine composition in the present invention has significant effects on the patients suffered from hyperglycemia, hyperlipidemia and hyperviscosity. Through treatment by 70 days, multiple high-value items in blood lipid and hemorheology were decreased to normal values or were close to the normal values. The fasting blood-glucose and the random blood glucose were greatly decreased. Notes: Western medicine treatment is not included in the above treatment.

1'7

Claims (2)

1. Claims

   1, A Mongolian medicine composition for treating diabetes, hyperlipidaemia and primary hyperviscosity with excellent curative effects, comprising the following raw materials in parts by weight: 1-2 parts of elecampane inula root, 3-6 parts of Fructus gardeniae, 10-15 parts of platycodon grandiflorus, 5-10 parts of coptis chinensis and 5-8 parts of sappanwood.
2. 2, The Mongolian medicine composition according to claim 1, comprising the following preferable ingredients: 1.5 parts of elecampane inula root, 4.5 parts of Fructusgardeniae, 12 parts of platycodon grandiflorus, 8 parts of coptis chinensis and 6 parts of sappanwood.